Issam Zineh

7.2k total citations · 2 hit papers
132 papers, 4.6k citations indexed

About

Issam Zineh is a scholar working on Pharmacology, Economics and Econometrics and Immunology. According to data from OpenAlex, Issam Zineh has authored 132 papers receiving a total of 4.6k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Pharmacology, 29 papers in Economics and Econometrics and 29 papers in Immunology. Recurrent topics in Issam Zineh's work include Pharmacogenetics and Drug Metabolism (36 papers), Pharmaceutical studies and practices (26 papers) and Health Systems, Economic Evaluations, Quality of Life (25 papers). Issam Zineh is often cited by papers focused on Pharmacogenetics and Drug Metabolism (36 papers), Pharmaceutical studies and practices (26 papers) and Health Systems, Economic Evaluations, Quality of Life (25 papers). Issam Zineh collaborates with scholars based in United States, China and Canada. Issam Zineh's co-authors include Michael Pacanowski, Yaning Wang, Shiew‐Mei Huang, Amber L. Beitelshees, C. Noel Bairey Merz, B. Delia Johnson, Rhonda M. Cooper‐DeHoff, Rajanikanth Madabushi, Janet Woodcock and Xinyuan Zhang and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Issam Zineh

130 papers receiving 4.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Physiologically Based Pharmacokinetic Modeling in Regulatory Science: An Update From the U.S. Food and Drug Administration’s Office of Clinical Pharmacology

2018 241 citations Yuching Yang, Xinyuan Zhang et al. Journal of Pharmaceutical Sciences profile →
Effect of Sunscreen Application Under Maximal Use Conditions on Plasma Concentration of Sunscreen Active Ingredients

2019 215 citations Jeffry Florian, Issam Zineh et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Issam Zineh United States	32	1.1k	996	867	629	536	132	4.6k
Anke H. Maitland‐van der Zee Netherlands	39	1.9k 1.8×	936 0.9×	1.0k 1.2×	893 1.4×	848 1.6×	295	6.6k
Russell A. Wilke United States	34	1.4k 1.3×	470 0.5×	1.2k 1.4×	854 1.4×	523 1.0×	93	4.5k
Andrea Jorgensen United Kingdom	32	1.4k 1.3×	509 0.5×	468 0.5×	287 0.5×	488 0.9×	107	3.7k
David J. Graham United States	33	369 0.4×	1.6k 1.6×	654 0.8×	982 1.6×	354 0.7×	115	5.6k
Christian Funck‐Brentano France	47	1.6k 1.5×	3.4k 3.4×	1.3k 1.5×	999 1.6×	645 1.2×	205	7.7k
Larisa H. Cavallari United States	40	3.1k 3.0×	1.3k 1.3×	685 0.8×	529 0.8×	1.0k 1.9×	198	5.3k
Caroline F. Thorn United States	35	2.0k 1.9×	405 0.4×	2.2k 2.5×	391 0.6×	969 1.8×	58	6.9k
In‐Jin Jang South Korea	40	1.2k 1.1×	293 0.3×	1.5k 1.7×	751 1.2×	777 1.4×	306	5.9k
Hui Quan United States	32	501 0.5×	1.2k 1.2×	1.3k 1.6×	1.4k 2.3×	162 0.3×	111	8.2k
Ute I. Schwarz Canada	37	2.0k 1.9×	863 0.9×	733 0.8×	696 1.1×	1.2k 2.2×	87	5.6k

Countries citing papers authored by Issam Zineh

Since Specialization

Citations

This map shows the geographic impact of Issam Zineh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Issam Zineh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Issam Zineh more than expected).

Fields of papers citing papers by Issam Zineh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Issam Zineh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Issam Zineh. The network helps show where Issam Zineh may publish in the future.

Co-authorship network of co-authors of Issam Zineh

This figure shows the co-authorship network connecting the top 25 collaborators of Issam Zineh. A scholar is included among the top collaborators of Issam Zineh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Issam Zineh. Issam Zineh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Liu, Qi, Hao Zhu, Karen M. Higgins, et al.. (2024). Using Machine Learning to Determine a Suitable Patient Population for Anakinra for the Treatment of COVID‐19 Under the Emergency Use Authorization. Clinical Pharmacology & Therapeutics. 115(4). 890–895. 7 indexed citations

Wang, Yow‐Ming, Ólanrewaju O. Okusanya, Bilal Abuasal, et al.. (2024). Clinical Pharmacology Approaches to Support Approval of New Routes of Administration for Therapeutic Proteins. Clinical Pharmacology & Therapeutics. 115(3). 440–451. 6 indexed citations

Weber, Benjamin, et al.. (2024). How debunking biases in research and development decisions could lead to more equitable healthcare?. Clinical and Translational Science. 17(7). e13880–e13880. 1 indexed citations

Madabushi, Rajanikanth, et al.. (2024). The US Food and Drug Administration's Model‐Informed Drug Development Meeting Program: From Pilot to Pathway. Clinical Pharmacology & Therapeutics. 116(2). 278–281. 9 indexed citations

Strauss, David G., Zhihua Li, Srikanth C. Nallani, et al.. (2024). Intranasal Naloxone Repeat Dosing Strategies and Fentanyl Overdose. JAMA Network Open. 7(1). e2351839–e2351839. 7 indexed citations

Shord, Stacy S., et al.. (2023). US Food and Drug Administration embraces using innovation to identify optimized dosages for patients with cancer. CPT Pharmacometrics & Systems Pharmacology. 12(11). 1573–1576. 6 indexed citations

Pacanowski, Michael, et al.. (2023). A Multistakeholder Perspective on Advancing Individualized Therapeutics. Clinical Pharmacology & Therapeutics. 114(5). 994–1001. 1 indexed citations

Li, Fang, Shengnan Du, Jeffry Florian, et al.. (2022). Model‐Based Approach to Selecting Pegfilgrastim Dose for Pharmacokinetic and Pharmacodynamic Similarity Studies in Biosimilar Development. Clinical Pharmacology & Therapeutics. 113(1). 62–70. 1 indexed citations

Guinn, Daphne, et al.. (2020). Communicating Immunogenicity-Associated Risk in Current U.S. FDA Prescription Drug Labeling: A Systematic Evaluation. Therapeutic Innovation & Regulatory Science. 54(6). 1363–1371. 1 indexed citations

10.

Maxfield, Kimberly, Daniel González, Qi Liu, et al.. (2020). Proceedings of a Workshop: Precision Dosing: Defining the Need and Approaches to Deliver Individualized Drug Dosing in the Real‐World Setting. Clinical Pharmacology & Therapeutics. 109(1). 25–28. 16 indexed citations

11.

Thway, Theingi M., et al.. (2019). Current Perspectives on Ligand-Binding Assay Practices in the Quantification of Circulating Therapeutic Proteins for Biosimilar Biological Product Development. The AAPS Journal. 22(1). 15–15. 3 indexed citations

12.

Yang, Yuching, Xinyuan Zhang, Jeffry Florian, et al.. (2019). Consideration of a Credibility Assessment Framework in Model‐Informed Drug Development: Potential Application to Physiologically‐Based Pharmacokinetic Modeling and Simulation. CPT Pharmacometrics & Systems Pharmacology. 9(1). 21–28. 112 indexed citations

13.

Nolin, Thomas D., George R. Aronoff, William H. Fissell, et al.. (2014). Pharmacokinetic Assessment in Patients Receiving Continuous RRT. Clinical Journal of the American Society of Nephrology. 10(1). 159–164. 35 indexed citations

14.

Huang, Shiew-Mei, Nicholas M. P. King, Yaning Wang, Ping Zhao, & Issam Zineh. (2013). The Utility of Modeling and Simulation in Drug Development and Regulatory Review. Journal of Pharmaceutical Sciences. 102(9). 2912–2923. 160 indexed citations

15.

Rogers, Hobart, Atul Bhattaram, Issam Zineh, et al.. (2012). CYP2D6 Genotype Information to Guide Pimozide Treatment in Adult and Pediatric Patients. The Journal of Clinical Psychiatry. 73(9). 1187–1190. 26 indexed citations

16.

Zineh, Issam & Shiew‐Mei Huang. (2011). Biomarkers in Drug Development and Regulation: a Paradigm for Clinical Implementation of Personalized Medicine. Biomarkers in Medicine. 5(6). 705–713. 19 indexed citations

17.

Gulati, Martha, Rhonda M. Cooper‐DeHoff, Candace McClure, et al.. (2009). Adverse Cardiovascular Outcomes in Women With Nonobstructive Coronary Artery Disease. Archives of Internal Medicine. 169(9). 843–843. 384 indexed citations

18.

Pacanowski, Michael, Issam Zineh, Haihong Li, et al.. (2008). Adrenergic gene polymorphisms and cardiovascular risk in the NHLBI-sponsored Women's Ischemia Syndrome Evaluation. Journal of Translational Medicine. 6(1). 11–11. 24 indexed citations

19.

Shin, Jaekyu, Maximilian T. Lobmeyer, Yan Gong, et al.. (2006). Relation of β2-Adrenoceptor Haplotype to Risk of Death and Heart Transplantation in Patients With Heart Failure. The American Journal of Cardiology. 99(2). 250–255. 71 indexed citations

20.

Aquilante, Christina L., Taimour Langaee, Peter L. Anderson, Issam Zineh, & Courtney V. Fletcher. (2006). Multiplex PCR-pyrosequencing assay for genotyping CYP3A5 polymorphisms. Clinica Chimica Acta. 372(1-2). 195–198. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact